Article Information
History
- July 25, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 25, 2021 - 19:04).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Sidney Ontai, MD, MBA1,*,
- Li Zeng, PhD2,
- Miguel Sierra Hoffman, MD1,
- Fernando Valerio Pascua, MD3,
- Vincent VanBuren, PhD, FAHA4 and
- Peter A McCollough, MD, MPH5
- 1Texas A&M University Health Science Center, Department of Primary Care and Population Health
- 2Texas A&M University School of Engineering, Department of Industrial and Systems Engineering
- 3Department of Critical Care, Hospital CEMESA, Cortés, Honduras
- 4Texas A&M University Health Science Center, Department of Medical Education
- 5Texas A & M College of Medicine, Baylor Dallas Campus, Dallas TX
- ↵*Corresponding Author and Reprint Address:
Sidney Ontai, MD, MBA, 501 East San Antonio Street, Victoria, TX, 77901, phone 361-582-0861, fax 361-788-6114, ontai{at}ontai.com
Posted July 25, 2021.
Early multidrug treatment of SARS-CoV-2 (COVID-19) and decreased case fatality rates in Honduras
